Kristie Grebe
Chief Scientific Officer Navigator Medicines, Inc.
Seminars
- Evaluating the clinical rationale for simultaneous OX40L and TNFα inhibition to address multiple inflammatory pathways driving HS pathogenesis and disease heterogeneity
- Reviewing Phase 1 safety, tolerability and pharmacokinetic findings supporting further development and potential once-monthly dosing in patients with HS
- Exploring how bispecific antibody approaches could improve upon TNFα monotherapy to deliver more durable responses and raise the standard of care in moderate-to-severe HS
Hidradenitis Suppurativa (HS) remains one of the most challenging inflammatory skin diseases to diagnose, treat, and manage long term. While therapeutic innovation in dermatology continues to accelerate, HS still faces significant unmet need, including delayed diagnosis, irreversible tissue damage, limited biomarkers, and comparatively slow translational progress. This workshop
will explore how earlier intervention strategies and emerging therapeutic approaches could shift HS management beyond reactive symptom control toward improving long-term outcomes and potentially modifying disease progression.
Attendees will gain insight into the evolving HS treatment landscape, the scientific and clinical barriers slowing progress, and what is needed to strengthen translational development in this underserved area of inflammatory disease.
Key Questions to be Addressed:
- How can earlier intervention influence long-term disease progression and tissue damage in HS?
- What evidence is needed to support earlier use of advanced therapies in HS care pathways?
- Why has HS seen comparatively limited preclinical and translational advancement compared with other inflammatory diseases?
- What lessons can HS learn from earlier biologic intervention strategies used in psoriasis, atopic dermatitis, and other chronic inflammatory conditions?
- How can the field move beyond symptom management toward disease modification and improved quality of life for patients living with HS?
